Suppr超能文献

评价两种粉末状局部可吸收止血剂在猪肝脏轻度至中度出血模型中的止血效果。

Evaluation of the Hemostatic Efficacy of Two Powdered Topical Absorbable Hemostats Using a Porcine Liver Abrasion Model of Mild to Moderate Bleeding.

机构信息

Ethicon, Inc, Johnson & Johnson, Somerville, New Jersey, USA.

NAMSA, Northwood, Ohio, USA.

出版信息

J Invest Surg. 2021 Nov;34(11):1198-1206. doi: 10.1080/08941939.2020.1792007. Epub 2020 Sep 15.

Abstract

INTRODUCTION

Topical hemostatic agents, used alone or in combination, have become common adjuncts to manage tissue and organ bleeding resulting from trauma and surgical procedures. Oxidized regenerated cellulose (ORC) is one of the most commonly used adjunctive hemostatic agents. The aim of the present study was to compare the hemostatic efficacy of a novel ORC-based product, SURGICEL® Powder Absorbable Hemostat (Surgicel-P) to that of HEMOBLAST™ Bellows (Hemoblast-B), a collagen-based combination powder.

METHODS

Using an established porcine liver abrasion model, we randomly tested Surgicel-P and Hemoblast-B in 60 experimental lesion sites (30 per product tested). Primary endpoints included hemostatic efficacy measured by absolute time to hemostasis (TTH) within 5 minutes. We also examined number of applications required to achieve hemostasis, and sustained hemostasis following saline irrigation of test sites that achieved hemostasis.

RESULTS

Surgicel-P demonstrated significantly higher hemostatic efficacy and lower TTH ( < 0.01) than Hemoblast-B. Surgicel-P-treated lesion sites achieved hemostasis in 73.3% of cases following one product application vs. 3.3% of Hemoblast-B-treated sites. Of all sites that were assessed, hemostasis was achieved and sustained following irrigation at 93.3% of Surgicel-P-treated sites vs. 50.0% of Hemoblast-B-treated sites. The average number of Surgicel-P applications per site was 51% lower than the average number of applications used for Hemoblast-B.

CONCLUSION

Surgicel-P provided more effective and sustained hemostasis and faster TTH than Hemoblast-B. Surgicel-P represents a novel clinical alternative to provide adjunctive control of diffuse mild and moderate bleeding. Surgicel-P combines an ORC powder formulation and a delivery system in a device that is particularly useful for application on large surfaces and difficult-to-access anatomical locations where application of other forms of topical hemostats may be impractical.

摘要

简介

局部止血剂,单独使用或联合使用,已成为处理创伤和手术引起的组织和器官出血的常用辅助手段。氧化再生纤维素(ORC)是最常用的辅助止血剂之一。本研究旨在比较一种新型 ORC 基产品 SURGICEL® Powder Absorbable Hemostat(Surgicel-P)与基于胶原的组合粉末 HEMOBLAST™ Bellows(Hemoblast-B)的止血效果。

方法

使用已建立的猪肝脏磨损模型,我们在 60 个实验病变部位(每个产品测试 30 个)中随机测试 Surgicel-P 和 Hemoblast-B。主要终点包括在 5 分钟内达到止血的绝对止血时间(TTH)来衡量止血效果。我们还检查了达到止血所需的应用次数,以及在达到止血的测试部位用生理盐水冲洗后的持续止血情况。

结果

Surgicel-P 的止血效果明显优于 Hemoblast-B,TTH 更低(<0.01)。Surgicel-P 治疗的病变部位中有 73.3%在单次产品应用后达到止血,而 Hemoblast-B 治疗的病变部位中只有 3.3%达到止血。在所有评估的部位中,93.3%的 Surgicel-P 治疗部位在冲洗后达到和维持止血,而 Hemoblast-B 治疗部位中只有 50.0%达到止血。Surgicel-P 治疗部位的平均应用次数比 Hemoblast-B 少 51%。

结论

Surgicel-P 比 Hemoblast-B 提供更有效和持续的止血效果以及更快的 TTH。Surgicel-P 代表了一种新的临床选择,可提供辅助控制弥漫性轻度和中度出血。Surgicel-P 将 ORC 粉末配方和给药系统结合在一个装置中,特别适用于在大面积和难以到达的解剖部位应用,在这些部位应用其他形式的局部止血剂可能不切实际。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验